Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
A double-blind, placebo-controlled, randomised phase 1/2a study to evaluate the safety, tolerability and pharmacokinetics of single and repeated subcutaneous ascending-doses of DX243 in healthy volunteers followed by an extension to assess 1-month safety and preliminary efficacy in patients with mild age-related hearing loss.
100 Clinical Results associated with Dendrogenix SA
0 Patents (Medical) associated with Dendrogenix SA
100 Deals associated with Dendrogenix SA
100 Translational Medicine associated with Dendrogenix SA